PGNY
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Progyny, Inc.
- Nom
- Progyny, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Plans
- Bourse
- NASDAQ
- Capitalisation
- $2.2B
- Employés
- 846
- PDG
- Pete Anevski
- Site web
- https://www.progyny.com
- Marché
- HQYOMDA
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 11 500 titres (~321 358,30 $ US)
- Insiders
- GORDON KEVIN K
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$466,338
Avg sell (VWAP, 90d window) $26.98 vs last close $29.12 (+7.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$154,480 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-10
- Liquidity
- Liquid $31,943,602/day · 20d vol
- Last synced
-
2026-10-22 21:10:58
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-14 | Cummings Melissa B | Sell · S S · 10b5-1 | 1,879 | $28.00 | ≈ $52,612 | Form 4 |
| 2026-09-23 | Swartz Allison | Sell · S S · 10b5-1 | 3,903 | $26.10 | ≈ $101,868 | Form 4 |
| 2026-09-10 | GORDON KEVIN K | Sell · S S · 10b5-1: not stated | 11,500 | $27.12 | ≈ $311,858 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2024-12-06 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2020-07-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-06-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-06-01 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-05-21 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
PGNY combines a strong liquidity profile (score 85) with solid operational fundamentals, but the catalyst score is weak (25) driven by insider selling from both executives and a Congressional member, which offsets the…
The first sentence of the analysis written for PGNY on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 2.73 · operating margin 6.6%
Suggested stop 25.93, nearest stored support minus 0.5 ATR(11.0% under the last close). Reward/risk to the next stored resistance is 1.24. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 Progyny (NASDAQ:PGNY) COO Sells $52,612.00 in Stock Progyny, Inc. (NASDAQ: PGNY - Get Free Report) COO Melissa Cummings sold 1,879 shares of the stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total transaction of $52,612.00. Following the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at
- 2026-10-15 Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women''s health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 – 24, 2026.
- 2026-10-08 Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock? Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 2026-10-07 PGNY or CRL: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
- 2026-10-07 Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI Progyny''s Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women''s health and family building solutions, today revealed key insights from the Company''s current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribute 1.2 million new covered lives from launches throughout the first half of 2027. Employers are now weighing how to best meet the complex needs of their workforce while simultaneously wrestling with the broader escalation in the overall medical cost trend.
- 2026-09-18 PGNY vs. CRL: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
- 2026-09-17 Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY''s Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.
- 2026-09-09 Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here''s What You Should Know The mean of analysts'' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 2026-09-03 Progyny, Inc. to Present at the Wells Fargo Healthcare Conference NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women''s health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.
- 2026-09-02 Hsbc Holdings PLC Makes New $760,000 Investment in Progyny, Inc. $PGNY Hsbc Holdings PLC acquired a new stake in shares of Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 26,394 shares of the company''s stock, valued at approximately $760,000. Several other large investors have also
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% | |
| Ebit Margin | 7.4% | 7.1% | 6.5% | 3.1% | 6.5% | |
| Ebitda Margin | 7.8% | 7.4% | 6.7% | 3.3% | 6.7% | |
| Operating Profit Margin | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% | |
| Pretax Profit Margin | 7.4% | 7.1% | 6.5% | 3.1% | 6.5% | |
| Continuous Operations Profit Margin | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | |
| Net Profit Margin | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | |
| Bottom Line Profit Margin | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | |
| Current Ratio | 2.726 | 2.803 | 3.444 | 2.719 | 2.616 | |
| Quick Ratio | 2.726 | 2.803 | 3.444 | 2.719 | 2.616 | |
| Solvency Ratio | 0.280 | 0.311 | 0.317 | 0.193 | 0.631 | |
| Cash Ratio | 0.555 | 0.963 | 0.523 | 0.753 | 0.925 | |
| Price To Earnings Ratio | 37.765 | 29.237 | 57.200 | 94.394 | 68.041 | |
| Price To Earnings Growth Ratio | 2.476 | -3.167 | 0.590 | -1.704 | 1.837 | |
| Forward Price To Earnings Growth Ratio | 2.476 | -3.167 | 0.590 | -1.704 | 1.837 | |
| Price To Earnings Diluted Ratio | 39.508 | 30.263 | 59.968 | 103.833 | 76.288 | |
| Price To Earnings Diluted Growth Ratio | 2.815 | -3.753 | 0.562 | -1.904 | 1.887 | |
| Price To Book Ratio | 4.241 | 3.739 | 6.384 | 7.618 | 17.816 | |
| Price To Sales Ratio | 1.698 | 1.352 | 3.245 | 3.650 | 8.962 | |
| Price To Free Cash Flow Ratio | 11.413 | 9.085 | 19.079 | 37.223 | 187.655 | |
| Price To Operating Cash Flow Ratio | 10.413 | 8.811 | 18.711 | 35.722 | 172.311 | |
| Debt To Assets Ratio | 0.037 | 0.032 | 0.026 | 0.014 | 0.024 | |
| Debt To Equity Ratio | 0.054 | 0.046 | 0.035 | 0.020 | 0.034 | |
| Debt To Capital Ratio | 0.051 | 0.044 | 0.034 | 0.020 | 0.033 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.439 | 1.438 | 1.367 | 1.440 | 1.422 | |
| Working Capital Turnover Ratio | 3.944 | 3.078 | 2.987 | 3.626 | 3.679 | |
| Operating Cash Flow Ratio | 1.039 | 1.062 | 1.015 | 0.504 | 0.263 | |
| Operating Cash Flow Sales Ratio | 0.163 | 0.153 | 0.173 | 0.102 | 0.052 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.912 | 0.970 | 0.981 | 0.960 | 0.918 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 7.581 | 9.294 | 9.738 | 10.423 | 3.010 | |
| Capital Expenditure Coverage Ratio | 11.417 | 33.137 | 51.815 | 24.806 | 12.230 | |
| Dividend Paid And Capex Coverage Ratio | 11.417 | 33.137 | 51.815 | 24.806 | 12.230 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 20.963 | 16.613 | 47.347 | 105.964 | 130.534 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 23.6% | ▲1.9% | ▲1.4% |
| Ebit Margin | 7.4% | ▲0.3% | ▲1.3% |
| Ebitda Margin | 7.8% | ▲0.4% | ▲1.4% |
| Operating Profit Margin | 6.6% | ▲0.8% | ▲1.1% |
| Pretax Profit Margin | 7.4% | ▲0.3% | ▲1.3% |
| Continuous Operations Profit Margin | 4.5% | ▼-0.1% | ▼-1.8% |
| Net Profit Margin | 4.5% | ▼-0.1% | ▼-1.8% |
| Bottom Line Profit Margin | 4.5% | ▼-0.1% | ▼-1.8% |
| Current Ratio | 2.726 | ▼-0.077 | ▼-0.136 |
| Quick Ratio | 2.726 | ▼-0.077 | ▼-0.136 |
| Solvency Ratio | 0.280 | ▼-0.030 | ▼-0.066 |
| Cash Ratio | 0.555 | ▼-0.408 | ▼-0.189 |
| Price To Earnings Ratio | 37.765 | ▲8.527 | ▼-19.563 |
| Price To Earnings Growth Ratio | 2.476 | ▲5.643 | ▲2.469 |
| Forward Price To Earnings Growth Ratio | 2.476 | ▲5.643 | ▲2.469 |
| Price To Earnings Diluted Ratio | 39.508 | ▲9.245 | ▼-22.464 |
| Price To Earnings Diluted Growth Ratio | 2.815 | ▲6.568 | ▲2.893 |
| Price To Book Ratio | 4.241 | ▲0.502 | ▼-3.718 |
| Price To Sales Ratio | 1.698 | ▲0.346 | ▼-2.083 |
| Price To Free Cash Flow Ratio | 11.413 | ▲2.328 | ▼-41.478 |
| Price To Operating Cash Flow Ratio | 10.413 | ▲1.602 | ▼-38.780 |
| Debt To Assets Ratio | 0.037 | ▲0.006 | ▲0.011 |
| Debt To Equity Ratio | 0.054 | ▲0.008 | ▲0.016 |
| Debt To Capital Ratio | 0.051 | ▲0.007 | ▲0.015 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.439 | ▲0.000 | ▲0.017 |
| Working Capital Turnover Ratio | 3.944 | ▲0.867 | ▲0.481 |
| Operating Cash Flow Ratio | 1.038 | ▼-0.024 | ▲0.262 |
| Operating Cash Flow Sales Ratio | 0.163 | ▲0.010 | ▲0.034 |
| Free Cash Flow Operating Cash Flow Ratio | 0.912 | ▼-0.057 | ▼-0.036 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 7.581 | ▼-1.712 | ▼-0.428 |
| Capital Expenditure Coverage Ratio | 11.417 | ▼-21.720 | ▼-15.264 |
| Dividend Paid And Capex Coverage Ratio | 11.417 | ▼-21.720 | ▼-15.264 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 20.963 | ▲4.349 | ▼-43.321 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.19B | $1.58B | $3.53B | $2.87B | $4.49B | |
| Enterprise value | $2.10B | $1.44B | $3.45B | $2.76B | $4.40B | |
| EV / Sales | 1.63x | 1.23x | 3.17x | 3.51x | 8.80x | |
| EV / Op. cash flow | 10.01x | 8.01x | 18.30x | 34.32x | 169.13x | |
| EV / Free cash flow | 10.97x | 8.26x | 18.66x | 35.77x | 184.19x | |
| EV / EBITDA | 20.96x | 16.61x | 47.35x | 105.96x | 130.53x | |
| Net debt / EBITDA | -0.84x | -1.66x | -1.07x | -4.32x | -2.45x | |
| Current ratio | 2.73x | 2.80x | 3.44x | 2.72x | 2.62x | |
| Income quality | 3.59x | 3.30x | 3.04x | 2.65x | 0.40x | |
| Graham number | $10 | $8 | $9 | $6 | $7 | |
| Graham net-net | $3 | $2 | $4 | $2 | $1 | |
| Tax burden | 61.3% | 65.3% | 87.8% | 124.2% | 202.8% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $349.4M | $304.1M | $454.5M | $274.3M | $159.7M | |
| Invested capital | $430.5M | $350.6M | $494.2M | $301.6M | $185.0M | |
| Return on assets | 7.9% | 9.0% | 8.2% | 5.6% | 18.4% | |
| Operating ROA | 12.6% | 9.9% | 9.6% | 5.2% | 10.6% | |
| Return on tangible assets | 8.2% | 9.2% | 8.3% | 5.7% | 19.0% | |
| Return on equity | 11.3% | 12.9% | 11.2% | 8.1% | 26.1% | |
| Return on invested capital | 9.6% | 10.0% | 9.5% | 6.1% | 12.4% | |
| Return on capital employed | 15.8% | 15.4% | 10.9% | 6.1% | 12.5% | |
| Earnings yield | 2.7% | 3.4% | 1.8% | 1.1% | 1.5% | |
| Free cash flow yield | 8.8% | 11.0% | 5.2% | 2.7% | 0.5% | |
| Capex / Op. cash flow | 8.8% | 3.0% | 1.9% | 4.0% | 8.2% | |
| Capex / Depreciation | 372.1% | 170.2% | 159.8% | 202.4% | 163.6% | |
| Capex / Sales | 1.4% | 0.5% | 0.3% | 0.4% | 0.4% | |
| SG&A / Sales | 17.0% | 15.9% | 16.2% | 18.3% | 15.9% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 10.2% | 11.0% | 11.3% | 12.8% | 6.7% | |
| Intangibles / Total assets | 3.5% | 2.8% | 1.6% | 2.2% | 3.5% | |
| Days sales outstanding | 62d | 74d | 81d | 111d | 98d | |
| Days payables outstanding | 46d | 38d | 54d | 64d | 58d | |
| Operating cycle | 62d | 74d | 81d | 111d | 98d | |
| Cash conversion cycle | 16d | 36d | 27d | 47d | 40d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years